Replies to post #146121 on NanoViricides Inc. (NNVC)

[drkazmd65]

About being wrong or not, certainly your prediction that they can't make cides reliably enough to go into a trial was wrong. As was the claim Diwan never intended and never would run a trial.

Agreed. The fact that Diwan did finally get something into a clinical trial does make all similar earlier predictions moot.

Now he just needs to get through a clinical trial, and get that data leveraged into a Phase II or a partnership with some bigger pharma company to get a Phase II or III started.

[4gh1rx]

NNVC - discussion

$NNVC - 11/13/2023 text release

$NNVC

__________________

NANOVIRICIDES TREATMENT FOR RSV
NanoViricides (NYSE American: NNVC), a leading developer of antiviral treatments through its nanomedicines platform, is developing a safe and effective alternative therapeutic for RSV. Its drug candidate, NV-387, has already been shown to not have the toxicity or side effects associated with Ribavirin, according to the company. It reports that in the recent pre-clinical animal study, NV-387 almost matched the efficacy of Ribavirin with no toxicity. This animal study was designed to mimic the lethal lung pneumonia in infants caused by RSV infection.
_________________________________
$NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** $NNVC *** NNVC

[4gh1rx]

$NNVC - Prospects

$NNVC

Re: Your post

Sound reasoning regarding the company's ultimate prospects. Well stated.
________________________________
$NNVC ***